China Grand Pharmaceutical and CDH Genetech Limited to acquire Sirtex Medical for $1.3bn.

China Grand Pharmaceutical and CDH Genetech Limited, two healthcare companies, agreed to acquire Sirtex Medical, a global life sciences and life technology company, which develop and provide effective cancer treatment products, for $1.3bn. “CDH recognizes Australia’s leadership in medical research and its world-class regulatory system. In particular, CDH sees significant potential to introduce Sirtex’s liver cancer treatment product into China,” CHD Genetech.